Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Phase 1 Terminated 47 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).

Timeline

Start: 2014-06
Primary completion: 2014-11
Completion: 2014-11

Outcome

Outcome not reported

Stopped: “To allow evaluation of emerging non-clinical data (see detailed description below)”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAK-137	Unknown	0.5 mg	Oral
Subject	TAK-137	Unknown	2 mg	Oral
Subject	TAK-137	Unknown	5 mg	Oral
Subject	TAK-137	Unknown	10 mg	Oral

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Summary

Timeline

Outcome

Drugs

Indications